Difference between revisions of "Zoledronic acid (Zometa)"
m (Text replace - "Class: " to "Class/mechanism: ") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf Zoledronic acid (Zometa) package insert]</ref><ref>[[Media:zoledronicacid.pdf | Zoledronic acid (Zometa) package insert (locally hosted backup)]]</ref><ref>[http://www.zometa.com Zometa manufacturer's site]</ref> | Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf Zoledronic acid (Zometa) package insert]</ref><ref>[[Media:zoledronicacid.pdf | Zoledronic acid (Zometa) package insert (locally hosted backup)]]</ref><ref>[http://www.zometa.com Zometa manufacturer's site]</ref> | ||
| Line 12: | Line 10: | ||
*Brief patient counseling information can be found on pages 21-22 of the [http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf#page=21 Zoledronic acid (Zometa) package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found on pages 21-22 of the [http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf#page=21 Zoledronic acid (Zometa) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/zoledronic-acid-patient-drug-information Zoledronic acid (Zometa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/zoledronic-acid-patient-drug-information Zoledronic acid (Zometa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/zoledronic-acid-patient-drug-information Zoledronic acid (Zometa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/zoledronic-acid-patient-drug-information Zoledronic acid (Zometa) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Acido Zoledronico, Aclasta, Blaztere, Cytozol, Reclast, Servycal, Tianqing YI TAI, Zhuo LAI, Zobone, Zoldonat, Zoledronate, Zoledronate Disodium, Zoledronic Acid, Zomera, Zometa, Zyfoss | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Bisphosphonates]] | ||
Revision as of 04:03, 10 January 2014
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Zoledronic acid (Zometa) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on pages 21-22 of the Zoledronic acid (Zometa) package insert[1]
- Zoledronic acid (Zometa) patient drug information (UpToDate)[5]
Also known as
Acido Zoledronico, Aclasta, Blaztere, Cytozol, Reclast, Servycal, Tianqing YI TAI, Zhuo LAI, Zobone, Zoldonat, Zoledronate, Zoledronate Disodium, Zoledronic Acid, Zomera, Zometa, Zyfoss